Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
610 in severe eosinophilic asthma (Phase II)
CTR20222078Phase 2Completed
- Sponsor
- Henlius
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 610 in asthma, sponsored by Henlius. Started Aug 2022; status: completed.
02
Drugs
610
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20222078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222078.